International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab-Reference-Cited by-同舟云学术

International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

Published:2023-12-06 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Zouboulis Christos C.¹²^ORCID,Prens Errol P.¹³,Sayed Christopher J.¹⁴^ORCID,Molina‐Leyva Alejandro¹⁵^ORCID,Bettoli Vincenzo¹⁶^ORCID,Romanelli Marco¹⁷^ORCID,Szepietowski Jacek C.¹⁸,Martinez Angela Llobet⁹,Kasparek Torben⁹,Lobach Iryna⁹,Wozniak Magdalena B.¹⁰,Ortmann Christine‐Elke⁹,Thomas Nicolas⁹,Bachhuber Teresa⁹,Ravichandran Shoba¹¹,Tzellos Thrasyvoulos¹¹²

Affiliation:

1. European Hidradenitis Suppurativa Foundation (EHSF) Dessau Germany

2. Departments of Dermatology, Venereology, Allergology and Immunology Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg Dessau Germany

3. Department of Dermatology Erasmus University Medical Center Rotterdam Rotterdam The Netherlands

4. Department of Dermatology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

5. Hidradenitis Suppurativa Unit, Instituto de Investigación Biosanitaria ibs and Servicio de Dermatologia Hospital Universitario Virgen de Las Nieves Granada Spain

6. Section of Dermatology and Infectious Diseases, Department of Medical Sciences University of Ferrara Ferrara Italy

7. Department of Dermatology University of Pisa Pisa Italy

8. Department of Dermatology, Venereology and Allergology Wroclaw Medical University Wrocław Poland

9. Novartis Pharma AG Basel Switzerland

10. Novartis Ireland Limited Dublin Ireland

11. Novartis Pharmaceuticals Corporation East Hanover New Jersey USA

12. Department of Dermatology Nordland Hospital Trust Bodø Norway

Funder

Novartis

Publisher

Wiley

Subject